Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model.
Lentivirus lytic peptides (LLPs) are derived from HIV-1 and have antibacterial properties. LLP derivatives (eLLPs) were engineered for greater potency against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Minimum bactericidal concentration (MBC) was determined in low and physiologic salt concentrations. MBC was decreased against SA and equivalent against PA in physiologic salt when compared to the parent compound LLP1. In a novel cystic fibrosis (CF) airway cell model, one derivative, WLSA5, reduced the number of adherent PA and only moderately affected CF cell viability. Overall, eLLPs are selectively toxic to bacteria and may be useful against CF airway infections.
Phadke
Shruti M
SM
Division of Pediatric Pulmonology, The Children's Hospital of Pittsburgh, 3705 Fifth Avenue, 15213, Pittsburgh, PA, USA.
Islam
Kazi
K
Deslouches
Berthony
B
Kapoor
Sunil A
SA
Beer Stolz
Donna
D
Watkins
Simon C
SC
Montelaro
Ronald C
RC
Pilewski
Joseph M
JM
Mietzner
Timothy A
TA
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001980:Bronchi / Q000378:metabolism; D016956:Burkholderia cepacia / Q000187:drug effects; D003550:Cystic Fibrosis / Q000378:metabolism*; D004847:Epithelial Cells / Q000378:metabolism; D015700:HIV Envelope Protein gp41 / Q000235:genetics / Q000494:pharmacology / Q000633:toxicity*; D015497:HIV-1 / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D010446:Peptide Fragments / Q000235:genetics / Q000494:pharmacology / Q000633:toxicity*; D015202:Protein Engineering; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; C116049:lentiviral lytic peptide type 1, Human immunodeficiency virus 1